GVR Report cover Single-use Bioprocess Tubing And Assemblies Market (2026 - 2033)Report

Single-use Bioprocess Tubing And Assemblies Market (2026 - 2033)

Size, Share & Trends Analysis Report By Product (Standalone Bioprocess Tubing, Tubing Assemblies), By Application (Fluid Transfer, Cell Culture & Mixing), By Solution, By End Use, By Region, And Segment Forecasts

Market Size, 2025

$3.9B

Market Estimate, 2026

$4.5B

Market Forecast, 2033

$12.5B

CAGR, 2026–2033

15.7%

Single-use Bioprocess Tubing And Assemblies Market Summary

The global single-use bioprocess tubing and assemblies market size was valued at USD 3.9 billion in 2025 and is projected to grow from USD 4.5 billion in 2026 to USD 12.5 billion by 2033, at a CAGR of 15.7% from 2026 to 2033. The market in North America dominated with a revenue share of 46.1% in 2025. This growth is driven by the expansion of continuous and integrated bioprocessing workflows, increasing biopharmaceutical R&D, and the expansion of vaccine and rapid response biomanufacturing capacity.

Single-use bioprocess tubing and assemblies market overview: Grand View Research estimates the global market size at USD 3.9 billion in 2025, projected to grow from USD 4.5 billion in 2026 to USD 12.5 billion by 2033 at a 15.7% CAGR, with regional growth momentum.Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, icon Download Free Sample Report

Key Market Trends & Insights

  • By product: Fluid transfer assemblies segment held the largest market share of 38.5% in 2025.
  • By application: Fluid transfer segment held the largest market share of 43.3% in 2025.
  • By solution: Customized solutions segment held the largest market share in 2025.
  • By end use: Biopharmaceutical and pharmaceutical companies segment held the largest market share of 54.2% in 2025.

Regional Highlights

  • Largest regional market: North America (46.1% revenue share, 2025)
  • Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
  • By country: U.S. held the largest market share in 2025

Market Size & Forecast

  • Market size in 2025: USD 3.9 Billion
  • Estimated market size in 2026: USD 4.5 Billion
  • Projected market size by 2033: USD 12.5 Billion
  • CAGR (2026-2033): 15.7%
Ask a question about the single-use bioprocess tubing and assemblies market
Try asking
✓Every figure cited from GVR research Prefer the report? Download free sample →

 

Single-use bioprocess tubing and assemblies market size and growth forecast (2023-2033)

To learn more about this report, icon Download Free Sample Report

Market Dynamics

The expansion of continuous and integrated bioprocessing workflows is emerging as a strong structural driver for the Single-use Bioprocess Tubing & Assemblies Market, primarily due to the need for closed, flexible, and contamination-controlled fluid handling across interconnected unit operations. Continuous bioprocessing shifts production away from discrete batch steps toward uninterrupted material flow, where upstream (perfusion or intensified cell culture) and downstream purification units operate in a synchronized manner. This architecture significantly increases dependence on sterile, modular, and rapidly configurable tubing assemblies that can maintain product integrity while enabling real-time connectivity between process steps. For instance, in April 2026, in the U.S., Avantor, Inc. expanded its Masterflex portfolio by integrating single-use assemblies and fluid handling systems, strengthening demand for scalable single-use bioprocess tubing and assemblies in biopharmaceutical manufacturing workflows.

"Unifying our portfolio under the Masterflex name makes it easier for customers to tailor solutions, for their specific processes and molecules, within a consistent framework, supporting smoother transition from development to production."

- Benoit Gourdier, Executive Vice President, Bioscience & Medtech Products, Avantor

The high validation complexity associated with multi-component disposable systems is a key restraint for the Single-use Bioprocess Tubing & Assemblies Market. Single-use assemblies typically integrate multiple components such as tubing, filters, connectors, manifolds, and clamps made from different polymer materials. Ensuring sterility, material compatibility, and compliance with extractables and leachables, and achieving consistent performance across all components, creates significant validation and documentation requirements for biopharmaceutical manufacturers.

Biopharmaceutical companies must perform extensive qualification studies before implementing these assemblies in commercial manufacturing. Even minor modifications in tubing material, supplier, or assembly configuration may require revalidation to comply with stringent regulatory standards from agencies such as the FDA and EMA. This increases operational costs, extends implementation timelines, and adds complexity to GMP manufacturing environments.

Single-use systems have gained significant traction in the biologics manufacturing sector, finding applications across various stages of the production process. These stages include the upstream process, media & buffer preparation, downstream process, and process-intermediate storage. Leading companies are increasingly outsourcing their manufacturing needs to Contract Manufacturing Organizations (CMOs) to focus on new product development. As a product progresses from clinical trials to full-scale commercial production, the development of corresponding single-use technology can occur concurrently at CMOs, expediting market entry.

In recent years, more CMOs have integrated single-use technologies into their bioprocesses, employing single-use assemblies to expedite processing and streamline process changeovers. The agility and turnaround time offered by single-use equipment can enhance CMO efficiency and reduce overall costs. Furthermore, an increasing number of CMOs have transitioned to predominantly single-use setups to save costs and reduce operating expenses & capital investments. Hence, such widespread adoption of single-use technologies by CMOs represents a promising growth opportunity in the market.

The integration of single-use bioprocess tubing and assemblies across multiple manufacturing facilities remains a significant challenge for the market. Biopharmaceutical companies operating across research, pilot-scale, and commercial production sites often face difficulties in standardizing tubing configurations, connector systems, manifold designs, and process interfaces. Variations in equipment platforms and supplier specifications can create compatibility issues during process scale-up and technology transfer, affecting operational efficiency and consistency.

The challenge is becoming increasingly pronounced as continuous bioprocessing, modular facilities, and multi-site manufacturing models are adopted. These environments require seamless coordination among upstream and downstream processing systems, automation platforms, and sterile fluid-transfer networks. In addition, regional regulatory differences and supply chain variability can complicate validation and harmonization efforts across global production facilities, increasing implementation complexity for manufacturers.

 

Market Characteristics

The single-use bioprocess tubing & assemblies market is characterized by continuous innovation focused on sterility assurance, contamination prevention, and process efficiency. Manufacturers are developing advanced tubing materials, pre-sterilized assemblies, and integrated fluid transfer systems to support high-performance biopharmaceutical manufacturing. Innovations are also targeting improved compatibility with cell & gene therapy workflows, vaccine manufacturing, and automated bioprocessing systems. Companies are integrating gamma-sterilized and cleanroom-manufactured assemblies to reduce validation requirements and minimize operational risks. For instance, in April 2026, Freudenberg Medical launched CleanAssure, an ISO Class 5 controlled cleanroom designed to provide washed, dried, and gamma-sterilized single-use assemblies for biopharmaceutical applications. The facility enhances sterility, reduces contamination risks, and supports process consistency for applications such as vaccine production, cell cultivation, fluid transfer, and fill-finish operation.

“CleanAssure allows us to support our customers beyond component manufacturing, by integrating controlled cleaning and sterilization into our single-use assembly services, we help reduce contamination risk, streamline validation activities, and support a reliable supply for our customers. We can now support customers with their entire component value chain and allow them to focus on their core manufacturing capability.”

Rudi Gall, VP, Global Pharma, Freudenberg Medical.

The market demonstrates a high level of collaboration among bioprocess solution providers, biopharmaceutical manufacturers, and contract development organizations. Strategic partnerships are increasingly being formed to improve supply chain reliability, accelerate product customization, and expand single-use technology integration across manufacturing facilities. Collaborations also support co-development of specialized tubing assemblies for complex biologics and cell therapy production processes. Companies are partnering with automation and fluid management providers to enhance workflow integration and process scalability. These partnerships help manufacturers address evolving regulatory requirements while improving operational flexibility and manufacturing efficiency. For instance, in September 2023, Repligen Corporation announced the acquisition of Metenova AB to strengthen its fluid management and single-use bioprocessing portfolio.

Single-use Bioprocess Tubing And Assemblies Industry Dynamics

To learn more about this report, icon Download Free Sample Report

Regulatory compliance plays a critical role in the single-use bioprocess tubing & assemblies market due to the stringent quality and sterility requirements associated with biopharmaceutical production. Regulatory agencies emphasize contamination control, extractables and leachables testing, material traceability, and validation of sterilization processes. Manufacturers are increasingly adopting ISO-certified cleanroom environments and gamma sterilization standards to comply with global bioprocessing regulations. The growing use of single-use systems in commercial biologics manufacturing has also increased the need for standardized documentation and quality assurance procedures. Compliance with FDA, EMA, and GMP regulations continues to influence product design, material selection, and manufacturing practices across the industry

Companies operating in the market are actively expanding their product portfolios to offer comprehensive fluid management and single-use bioprocessing solutions. Product expansion strategies focus on integrating tubing, connectors, pumps, mixers, and customized assemblies into unified platforms that support end-to-end manufacturing workflows. Manufacturers are also introducing application-specific assemblies for upstream processing, fill-finish operations, and cell therapy manufacturing. Increasing demand for scalable and modular systems is driving the development of engineered-to-order solutions compatible with both pilot-scale and commercial production environments. These expansions enable suppliers to improve process integration, operational flexibility, and customer-specific customization capabilities. For instance, in April 2026, Avantor Inc. expanded and unified its Masterflex fluid management portfolio, adding peristaltic pumps, tubing, single-use assemblies, mixers, and engineered-to-order fluid-handling systems for bioprocess manufacturing. The expanded portfolio is designed to improve secure fluid transfer, process scalability, and integration across R&D, pilot-scale, and commercial biopharmaceutical production workflows.

Regional expansion activities in the single-use bioprocess tubing & assemblies market are increasing as manufacturers seek to strengthen supply chain resilience and support growing biologics production capacity worldwide. Companies are expanding manufacturing facilities, cleanroom operations, and distribution networks across North America, Europe, and Asia Pacific to address rising demand from biopharmaceutical and cell therapy sectors. Asia Pacific is emerging as a major investment destination due to expanding biologics manufacturing infrastructure and increasing outsourcing activities. Regional expansion also helps suppliers improve lead times, reduce logistics complexity, and ensure localized technical support for customers. Additionally, companies are investing in strategically located production facilities to enhance business continuity and meet regional regulatory standards.

Case Study: Standardized Single Use Assemblies Supporting Flexible Biopharmaceutical Manufacturing

Background

The rapid adoption of single-use technologies (SUTs) in biopharmaceutical manufacturing has increased the demand for flexible, scalable, and contamination-free production systems. However, highly customized single-use assemblies often create interoperability limitations, supply chain dependencies, and operational inefficiencies.

To address these challenges, biopharmaceutical manufacturers increasingly adopted standardized modular single-use tubing assemblies and aseptic connector systems to simplify integration across multiple processing platforms.

Challenge

Manufacturers using customized single-use systems faced several operational challenges, including:

  • Vendor lock-in due to proprietary consumables and connectors

  • Limited compatibility between different supplier systems

  • Long procurement lead times for custom assemblies

  • Supply chain disruptions and inventory redundancies

  • Difficulty scaling processes across multi-product facilities

These issues increased manufacturing complexity, operational costs, and risks related to production continuity.

Solution

Industry experts promoted the use of standardized modular single-use assemblies consisting of interchangeable tubing and connector components that could be configured for multiple bioprocessing applications.

The modular approach included components such as:

  • Wye, tee, and cross tubing assemblies

  • Inline filter assemblies

  • Sample assemblies

  • Tubing jumpers and manifolds

  • Aseptic sterile connectors and tubing welders

These standardized assemblies enabled plug-and-play integration across upstream and downstream operations while supporting fully closed aseptic processing systems. The approach also allowed manufacturers to create scalable configurations for batch, fed batch, and continuous bioprocessing applications.

Outcomes

  • Improved process flexibility and scalability across facilities

  • Reduced vendor lock-in and enhanced supply chain resilience

  • Faster assembly integration and simplified operator training

  • Lower inventory redundancies and reduced procurement complexity

  • Improved aseptic processing and contamination control

The case highlights the growing importance of standardized single-use tubing assemblies and modular fluid management systems in the global single-use bioprocess tubing & assemblies market, particularly for biologics, vaccine, and cell & gene therapy manufacturing.

Product Insights

The fluid transfer assemblies segment held the largest market share of 38.5% in 2025. This assembly play the significant role in the sterile transfer of media, buffers, process fluids, and biologic products across biopharmaceutical manufacturing operations. These assemblies typically integrate tubing, connectors, manifolds, clamps, filters, and bags into ready-to-use fluid management systems that support contamination-free and closed-system processing environments. Fluid transfer assemblies are widely utilized in upstream processing, downstream purification, sampling, and fill-finish applications.

The standalone bioprocess tubing segment is expected to grow at the fastest CAGR of 17.7% over the forecast period. This is due to widely used for sterile fluid transfer, media handling, buffer transfer, sampling, filtration, and fill-finish operations across biopharmaceutical manufacturing facilities. The standalone bioprocess tubing segment includes silicone tubing, thermoplastic elastomer (TPE) tubing, peristaltic pump tubing, and high-purity transfer tubing used across upstream and downstream bioprocessing workflows. These tubing systems support closed-system processing while reducing contamination risks, cleaning validation requirements, and operational downtime associated with conventional stainless-steel systems. Rising production of biologics, vaccines, biosimilars, and cell & gene therapies is significantly driving demand for high-performance disposable tubing solutions.

Application Insights

The fluid transfer segment held the largest market share of 43.3% in 2025. This dominance is due to the extensive requirement for sterile movement of media, buffers, biologics, and process fluids across biopharmaceutical manufacturing operations. These systems are widely utilized in upstream processing, downstream purification, and fill-finish workflows to maintain contamination-free fluid handling while reducing cleaning validation and operational downtime.

The cell culture & mixing segment is expected to grow at the fastest CAGR of 17.1% during the forecast period from 2026 to 2033 in the single-use bioprocess tubing & assemblies market. Cell culture and mixing operations extensively rely on single-use tubing & assemblies for the sterile transfer of media, nutrients, gases, and buffers between bioreactors, mixing systems, and storage containers. These systems play a critical role in maintaining closed, contamination-free manufacturing environments across biologics, vaccine, and advanced therapy production workflows. The increasing adoption of single-use bioprocessing technologies to improve operational flexibility, reduce cross-contamination risks, and support scalable manufacturing is further driving segment growth.

Solution Insights

The customized solutions segment dominated the market in 2025, and is expected to grow at the fastest CAGR over the forecast period.  This is due to the increasing demand for application-specific fluid management systems across biologics, vaccines, and cell & gene therapy manufacturing. The customized solutions are specifically designed to meet unique bioprocessing requirements, including flow configuration, tubing length, connector integration, filtration setup, manifold design, and equipment compatibility. Customized assemblies help manufacturers improve process flexibility, reduce manual intervention, and support closed-system processing environments.

The standard solutions segment is expected to grow at a significant CAGR over the forecast period, due to their broad utilization in routine fluid transfer, media handling, sampling, and filtration operations across biopharmaceutical manufacturing facilities. These pre-configured systems typically include standardized tubing assemblies, manifolds, connectors, clamps, and transfer components designed to simplify installation and support consistent manufacturing operations.

End Use Insights

Biopharmaceutical and pharmaceutical companies dominated the market, accounting for 54.2% of revenue in 2025. This dominance is driven by the widespread adoption of disposable fluid management systems in biologics, vaccines, biosimilars, and injectable drug manufacturing. These companies use single-use tubing and assembly systems for sterile fluid transfer, media handling, sampling, storage, and fill-finish applications to improve manufacturing flexibility and reduce contamination risks. The growth of closed-system manufacturing and modular production facilities is driving demand for high-purity tubing assemblies and integrated fluid transfer systems. Manufacturers adopt disposable technologies to reduce cleaning validation, minimize downtime, and improve production turnaround times in commercial facilities.

In addition, growing investments in biologics manufacturing capacity are further supporting market growth. For instance, in April 2024, FUJIFILM invested an additional USD1.2 billion in its North Carolina biologics facility, increasing total investment to over USD 3.2 billion and adding eight 20,000-liter bioreactors for large-scale biologics production.

Single-use Bioprocess Tubing And Assemblies Market Share

To learn more about this report, icon Download Free Sample Report

The Cell & gene therapy developers’ segment is anticipated to register the fastest CAGR over the forecast period from 2026 to 2033. The increasing commercialization of advanced therapies is driving demand for highly sterile and closed-system manufacturing environments. Cell & gene therapy developers extensively use single-use tubing assemblies, cryogenic-compatible transfer systems, and sterile fluid-handling technologies for cell processing, media transfer, formulation, and final fill applications.

In addition, the complexity and sensitivity of cell & gene therapy workflows are significantly driving demand for low hold-up volume tubing, sterile connectors, and customized transfer assemblies designed to minimize contamination risks and maintain product integrity. Key players are focusing on cryogenic-compatible materials, reconnectable systems, and automation-ready tubing assemblies to support evolving advanced therapy manufacturing workflows.

Regional Insights

North America dominated the single-use bioprocess tubing & assemblies market, accounting for 46.1% of revenue in 2025. The regional market growth is driven by the strong presence of biopharmaceutical manufacturers, increasing biologics production, and the widespread adoption of single-use technologies across upstream and downstream bioprocessing operations. The growing demand for contamination-free fluid management systems, the expansion of cell & gene therapy manufacturing, and rising investments in biomanufacturing infrastructure further support market growth. In addition, technological advancements in sterile tubing assemblies, integrated fluid-transfer systems, and customized single-use solutions are driving increased adoption across commercial-scale manufacturing facilities.

Single-use Bioprocess Tubing And Assemblies Market Trends, by Region, 2026 - 2033

To learn more about this report, icon Download Free Sample Report

U.S. Single-use Bioprocess Tubing & Assemblies Market Trends

Single-use bioprocess tubing & assemblies market in the U.S. is dominated by the region due to the presence of large-scale biopharmaceutical manufacturing facilities and advanced biologics production capabilities. The country continues to see strong investment in monoclonal antibodies, vaccines, and cell & gene therapies, which require highly efficient, sterile fluid-transfer systems. Increasing adoption of single-use assemblies to improve manufacturing flexibility, reduce cross-contamination risks, and optimize operational efficiency is further driving market growth. In addition, growing investments in bioprocess automation and continuous manufacturing technologies are accelerating the demand for customized tubing assemblies and integrated fluid management systems.

Europe Single-use Bioprocess Tubing & Assemblies Market Trends

Europe represents a significant market for single-use bioprocess tubing & assemblies due to the strong presence of established biopharmaceutical companies and advanced manufacturing infrastructure. Countries such as Germany, the UK, Switzerland, France, and Italy are actively investing in biologics manufacturing and advanced therapy production facilities. The increasing adoption of single-use systems to support flexible, scalable manufacturing operations is driving market growth across the region. Furthermore, stringent regulatory standards regarding sterility assurance, contamination control, and process validation are encouraging manufacturers to adopt high-quality single-use tubing and assembly solutions.

The market for single-use bioprocess tubing & assemblies in UK is growing due to an increasing government support for life sciences and domestic biomanufacturing expansion drives regional market growth. Investments in advanced therapy manufacturing centers, biologics production, and cell & gene therapy research are driving the demand for sterile and customizable fluid transfer systems. In addition, collaborations between research institutes, biotechnology companies, and contract manufacturing organizations are supporting the development and commercialization of advanced single-use technologies. The growing focus on reducing operational complexity and improving process efficiency is also accelerating the adoption of tubing assemblies and fluid handling systems across the country.

Germany single-use bioprocess tubing & assemblies market is experiencing significant growth in the single-use bioprocess tubing & assemblies market, driven by the strong presence of biotechnology companies, biopharmaceutical manufacturers, and engineering-driven process innovation. The country’s advanced manufacturing capabilities and increasing investments in biologics and biosimilar production are driving demand for high-performance fluid-transfer and sterile-tubing systems. In addition, contract development and manufacturing organizations (CDMOs) are expanding their single-use bioprocessing capacity to support growing outsourcing activities. The growing focus on automation and process optimization is further driving the adoption of integrated tubing and assembly solutions in Germany.

Asia Pacific Single-use Bioprocess Tubing & Assemblies Market Trends

Asia Pacific is anticipated to grow at the fastest over the forecast period from 2026 to 2033. This is driven by expanding biopharmaceutical manufacturing activities in China, India, South Korea, and Japan. Factors such as improving healthcare infrastructure, increasing investments in biotechnology, and rising adoption of biologics are supporting market expansion. The growing presence of contract manufacturing organizations and the increasing outsourcing of bioprocessing activities are also driving demand for single-use tubing assemblies and fluid transfer systems. Moreover, global manufacturers are expanding their regional presence to strengthen supply chains and support increasing production requirements in emerging Asian markets.

The China single-use bioprocess tubing & assemblies market is growing significantly due to increasing investments in domestic biopharmaceutical manufacturing and rising demand for biologics and biosimilars. Government initiatives supporting biotechnology innovation and local manufacturing capabilities are accelerating the adoption of advanced bioprocessing technologies. In addition, international companies are expanding partnerships and manufacturing operations in China to strengthen regional supply chains and improve market access. The rapid expansion of biologics production facilities and increasing demand for contamination-free manufacturing processes are further driving the adoption of single-use tubing systems and customized fluid transfer assemblies across the country.

Latin America Single-use Bioprocess Tubing & Assemblies Market Trends

The Latin America single-use bioprocess tubing & assemblies market is experiencing steady growth due to the expansion of the biotechnology and biopharmaceutical sectors in countries such as Brazil, Mexico, and Argentina. Increasing healthcare investments and rising demand for biologics and biosimilars are supporting the adoption of flexible and cost-effective bioprocessing technologies. Single-use tubing assemblies are gaining traction as manufacturers seek to reduce cleaning requirements, lower operational costs, and improve production efficiency. However, dependence on imported technologies and limited local manufacturing infrastructure may moderately restrain market growth across the region.

Middle East & Africa Single-use Bioprocess Tubing & Assemblies Market Trends

The Middle East & Africa single-use bioprocess tubing & assemblies market is expected to significantly during the forecast period. Growth is driven by increasing investments in pharmaceutical manufacturing, expanding healthcare infrastructure, and the gradual development of biotechnology capabilities across the region. Countries such as the UAE and Saudi Arabia are investing in advanced healthcare and life sciences infrastructure to strengthen domestic pharmaceutical production. South Africa also represents a key market due to its relatively developed healthcare and research ecosystem. However, limited skilled workforce availability and lower R&D expenditure in several countries may continue to challenge market expansion in the region.

Key Single-use Bioprocess Tubing & Assemblies Company Insights

The market players operating in the single-use bioprocess tubing & assemblies market are adopting product approval to increase the reach of their products in the market, improve their availability in diverse geographical areas, and expand to enhance production/research activities. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key Single-use Bioprocess Tubing & Assemblies Companies

The following key companies have been profiled for this study on the single-use bioprocess tubing & assemblies market

  • Thermo Fisher Scientific Inc.

  • Merck KGaA

  • Sartorius AG

  • Danaher Corporation

  • Avantor Inc.

  • Saint-Gobain Life Sciences

  • Entegris Inc.

  • Foxx Life Sciences

  • Eldon James

  • Repligen Corporation

  • Parker Hannifin Corp

  • Corning Incorporated

  • Watson-Marlow Fluid Technology Solutions (Spirax Group plc)

  • Kuhner AG

Competitive Benchmarking

Operating Strategies

Competitive Edge

Weaknesses

Mature Players: Thermo Fisher Scientific Inc.

  •  Expand single-use bioprocess portfolios through advanced tubing assemblies, sterile fluid transfer systems, and customized flow-path solutions.
  • Strengthen global biopharmaceutical manufacturing presence through strategic partnerships, capacity expansion, and an integrated bioprocess platform.
 
  • Strong global distribution networks and established relationships with major biopharmaceutical manufacturers.
  • Broad product portfolios covering standalone tubing, fluid transfer assemblies, filtration systems, and customized single-use solutions.

.

  • High dependence on biopharmaceutical capital expenditure cycles and large-scale biologics manufacturing investments.
  • Complex supply chains and stringent regulatory requirements increase operational and validation costs.

Emerging Players: Foxx Life Sciences

  • Expand market visibility through OEM partnerships, flexible manufacturing capabilities, and targeted regional distribution strategies.
  • Emphasize the development of standard, made-to-order (MTO), and fully customized single-use tubing and assembly systems tailored to specific bioprocessing requirements.
 
  • Greater flexibility in custom product development and faster response to customer-specific assembly requirements.
  • Specialized expertise in high-purity tubing materials, compact single-use systems, and low-volume bioprocess applications.

 

  • Limited global manufacturing footprint and comparatively lower brand recognition than established market leaders.
  • Smaller product portfolios and reduced scalability for large biopharmaceutical manufacturing projects.

Get access to detailed company insights of key market participants. To know more request a free sample copy

Recent Development

  • In April 2026, Feudenberg Medical launched CleanAssure, an ISO Class 5 controlled cleanroom designed to provide washed, dried, and gamma-sterilized single-use assemblies for biopharmaceutical applications. The facility enhances sterility, reduces contamination risks, and supports process consistency for applications such as vaccine production, cell cultivation, fluid transfer, and fill-finish operation.

“CleanAssure allows us to support our customers beyond component manufacturing, by integrating controlled cleaning and sterilization into our single-use assembly services, we help reduce contamination risk, streamline validation activities, and support a reliable supply for our customers. We can now support customers with their entire component value chain and allow them to focus on their core manufacturing capability.”

- Rudi Gall, vp, global pharma, Freudenberg Medical.

  • In February 2025, Saint-Gobain Life Sciences introduced C-Flex Advance Bio tubing designed for weldable sterile fluid transfer applications in single-use biopharmaceutical manufacturing.

Single-use Bioprocess Tubing And Assemblies Market Report Scope

Report Attribute

Details

Market size in 2025

USD 3.9 billion

Estimated market size in 2026

USD 4.5 billion

Projected market size by 2033

USD 12.5 billion

Growth rate

CAGR of 15.7% from 2026 to 2033

Base year for estimation

2025

Historical data

2021 - 2024

Forecast period

2026 - 2033

Quantitative units

Revenue in USD million, CAGR from 2026 to 2033

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, solution, end use, and region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Mexico, Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Thermo Fisher Scientific Inc.; Merck KGaA; Sartorius AG; Danaher Corporation; Avantor Inc.; Saint-Gobain Life Sciences; Entegris Inc.; Foxx Life Sciences; Eldon James; Repligen Corporation; Parker Hannifin Corp; Corning Incorporated; Watson-Marlow Fluid Technology Solutions (Spirax Group plc); Kuhner AG

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Global Single-use Bioprocess Tubing And Assemblies Market Report Segmentation

This report forecasts revenue growth and analyzes the latest trends in each of the sub-segments from 2021 to 2033. Grand View Research has segmented the global market by product, application, solution, end-use, and region for this purpose:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)

    • Standalone Bioprocess Tubing

      • Silicone Tubing

      • Thermoplastic Elastomer (TPE) Tubing

      • Fluoropolymer-based Tubing

      • Other Thermoplastic Tubing

    • Tubing Assemblies

      • Standard Tubing Assemblies

      • Customized Tubing Assemblies

      • Connector-integrated Tubing Assemblies

      • Sampling & Transfer Tubing Sets

    • Fluid Transfer Assemblies

    • Other Tubing-centric Assemblies

  • Application Outlook (Revenue, USD Million, 2021 - 2033)

    • Fluid Transfer

    • Cell Culture & Mixing

    • Sampling

    • Fill-finish Applications

    • Storage & Media Handling

  • Solution Outlook (Revenue, USD Million, 2021 - 2033)

    • Customized Solutions

    • Standard Solutions

  • End Use Outlook (Revenue, USD Million, 2021 - 2033)

    • Biopharmaceutical & Pharmaceutical Companies

    • CROs & CMOs

    • Cell & Gene Therapy Developers

    • Academic & Research Institutes

  • Regional Outlook (Revenue, USD Million, 2021 - 2033)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • China

      • India

      • Japan

      • South Korea

      • Australia

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Delivered Customizations

This report has been delivered with the following In-depth customizations

Client Request

Customization Delivered

Value Adds

Company-level analysis by value, volume, and market share at global and regional level

Included competitive benchmarking of key market participants based on revenue share, product portfolio, regional presence, and strategic developments

Assisted in evaluating competitive positioning, market concentration, and strategic decision-making

Company level ASP/Unit price trends and Analysis

Delivered assessment of tubing and assembly compatibility across upstream, downstream, fill-finish, and fluid management applications, including integration with bioprocess equipment

Supported understanding of process efficiency, contamination control, and operational flexibility benefits

Biopharmaceutical capacity expansion & investment analysis

Included analysis of recent investments, facility expansions, cleanroom developments, and biomanufacturing capacity enhancement initiatives by major industry participants

Helped identify future demand trends, supply chain expansion opportunities, and emerging manufacturing capabilities

Frequently Asked Questions About This Report

About the Author(s)

Biotechnology Research Team

Healthcare · Biotechnology

This report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.

Last Updated:

Speak to Analyst

Trusted market insights - try a free sample

See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.

logo
GDPR & CCPA Compliant
logo
ISO 9001 Certified
logo
ISO 27001 Certified
logo
ESOMAR Member
Grand View Research is trusted by industry leaders worldwide
client logo
client logo
client logo
client logo
client logo
client logo